DACS
ONC

Dymon Asia Capital (Singapore)’s BeOne Medicines Ltd ONC Stock Holding History

Dymon Asia Capital (Singapore)’s Portfolio ONC Stock Details ONC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-2,200
Closed -$568K – 193
2020
Q4 		$568K Buy
+2,200
New +$606K 0.13% 81

Other funds holding ONC

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Dymon Asia Capital (Singapore)'s ONC Position: Q1 2021 in Review

Dymon Asia Capital (Singapore) sold out of BeOne Medicines Ltd (ONC) in Q1 2021, closing a stake of 2,200 shares — an estimated $568K sold.

Dymon Asia Capital (Singapore) first reported a position in ONC in Q4 2020 and held it in 1 quarter. The position peaked at $568K in Q4 2020. 252 funds tracked by Wall St. Rank hold ONC as of Q1 2021.

  • Dymon Asia Capital (Singapore) reported no remaining BeOne Medicines Ltd position as of Q1 2021 after selling out during the quarter.
  • Dymon Asia Capital (Singapore) sold 2,200 BeOne Medicines Ltd shares in Q1 2021, an estimated $568K.
  • Dymon Asia Capital (Singapore) first reported a position in BeOne Medicines Ltd in Q4 2020 and held it in 1 quarter.
  • Dymon Asia Capital (Singapore)'s BeOne Medicines Ltd position peaked at $568K in Q4 2020.
  • 252 funds tracked by Wall St. Rank held BeOne Medicines Ltd as of Q1 2021.

Based on Dymon Asia Capital (Singapore)'s 13F filing for Q1 2021, filed 14 May 2021.